Richard F. Pops
Director and CEO, Alkermes plc at Alkermes plc
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Neurocrine Biosciences Inc.
Director
Alkermes plc
Director · Director and CEO, Alkermes plc
Chief executive roles
Alkermes plc
· Director and CEO, Alkermes plc
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2024 | Neurocrine Biosciences Inc. | Option exercise | +23,200 | $42.76 | $992,032 |
| Mar 13, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −23,200 | $140.33 | $3,255,656 |
| Mar 11, 2024 | Neurocrine Biosciences Inc. | Option exercise | +100 | $42.76 | $4,276 |
| Mar 11, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −100 | $140.00 | $14,000 |
| Mar 8, 2024 | Neurocrine Biosciences Inc. | Option exercise | +1,700 | $42.76 | $72,692 |
| Mar 8, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −1,700 | $140.05 | $238,085 |
| Feb 20, 2024 | Neurocrine Biosciences Inc. | Option exercise | +15,000 | $12.98 | $194,700 |
| Feb 20, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −15,000 | $132.47 | $1,987,050 |
| Feb 8, 2024 | Alkermes plc | Grant or award | +218,551 | — | — |
| Feb 8, 2024 | Alkermes plc | Shares withheld for tax | −91,757 | $26.77 | $2,456,335 |
| Feb 21, 2023 | Alkermes plc | Option exercise | +32,400 | — | — |
| Feb 21, 2023 | Alkermes plc | Shares withheld for tax | −14,386 | $27.77 | $399,499 |
| Feb 20, 2023 | Alkermes plc | Grant or award | +119,713 | — | — |
| Feb 20, 2023 | Alkermes plc | Shares withheld for tax | −53,145 | $28.07 | $1,491,780 |
| Jan 3, 2023 | Neurocrine Biosciences Inc. | Option exercise | +15,000 | $12.71 | $190,650 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.